Business
CARsgen Therapeutics Announces 2025 Interim Results
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results.
About this update from Huadong Medicine Co., Ltd. Class A
[{"type":"text","content":"SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results.","length":205,"tagName":"p"},{"type":"text","content":"Business Highlights","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash and bank balances were around RMB1,261 million as of June 30, 2025. Cash and cash equivalents and deposits at the end of 2025 are expected to be not less than RMB1,100 million. We expect to have adequate cash into the 2028 excluding subsequent cash inflows.","length":262,"tagName":"p"}]},{"val":[{"type":"text","content":"During H1 2025, certification and regulatory filings for zevor-cel have been completed in more than 20 provinces or cities. CARsgen has received a total of 111 confirmed orders from its commercialization partner Huadong Medicine.","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satri-cel.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"The results of satri-cel confirmatory Phase II trial in China have been published in The Lancet and at the 2025 ASCO Annual Meeting.","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Multiple allogeneic CAR-T products are in development, covering treatment areas such as hematologic malignancies, solid tumors, and autoimmune diseases.","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"CARsgen introduced Zhuhai SB Xinchuang to accelerate allogeneic CAR-T development in mainland China.","length":100,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1034,"olType":false},{"type":"text","content":"Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "In the first half of 2025, we made significant strides across technology innovation, product development, and commercialization. Zevor-cel sales surged, while satri-cel became the world's first CAR-T targeting solid tumors to file an NDA. We are also advancing multiple allogeneic CAR-T therapies to enhance clinical outcomes and expand patient access."","length":501...